Bioventus Inc. (BVS) vs Kura Oncology, Inc. (KURA)
A side-by-side comparison of Bioventus Inc. and Kura Oncology, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BVS
Bioventus Inc.
$13.29HealthcareDelayed quote: Oct 6, 2026, 12:45 PM EDT
KURA
Kura Oncology, Inc.
$10.71HealthcareDelayed quote: Oct 6, 2026, 12:40 PM EDT
Total return — BVS vs KURA
growth of $100 · dividends reinvested · last 6yBVS -29.6% (-5.7%/yr)KURA -69.7% (-18.0%/yr)BVS compounded faster over this window
BVS KURA
BVS vs KURA: by the numbers
- •KURA is the larger company ($951M vs $901M market cap).
- •BVS is profitable (9.36% net margin) while KURA runs a net loss (-384.30%).
Metrics side by side
Valuation
| Metric | BVS | KURA |
|---|---|---|
| P/E ratio | 17.26 | N/A |
| Forward P/E | 17.07 | N/A |
| P/S ratio | 1.55 | 12.31 |
| P/B ratio | 3.94 | 19.63 |
| EV / EBITDA | 10.60 | N/A |
| FCF yield | 10.47% | N/A |
Profitability
| Metric | BVS | KURA |
|---|---|---|
| Gross margin | 68.00% | 94.73% |
| Operating margin | 10.63% | -449.94% |
| Net margin | 9.36% | -384.30% |
| ROE | 23.86% | -612.78% |
| ROIC | 11.37% | -67.13% |
Growth (annualized)
| Metric | BVS | KURA |
|---|---|---|
| Revenue CAGR (5Y) | 11.82% | N/A |
| EPS CAGR (5Y) | -5.03% | N/A |
| FCF CAGR (5Y) | 43.36% | N/A |
| Total return CAGR (5Y) | -0.81% | -10.73% |
Frequently asked
- Is BVS or KURA more profitable?
- BVS runs the higher net margin — BVS at 9.36% versus KURA at -384.30%.
- How have BVS and KURA total returns compared?
- Over the past 5 years, BVS delivered -0.81% and KURA delivered -10.73% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Bioventus P/E ratioBioventus ROEKura Oncology ROEBioventus operating marginKura Oncology operating marginBioventus revenue growthKura Oncology revenue growthBioventus free cash flowKura Oncology free cash flow
Bioventus & Kura Oncology appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.